


REMARKS

This is a supplemental preliminary amendment to the above-identified application. The Specification has been amended to disclose that this application is a divisional application of U.S. Patent Application Ser. No. 09/528,978, filed 3/21/2000, which claims priority to U.S. Provisional Patent Application Ser. No. 60/128,136, filed 04/07/1999. Claim 1 has been amended to recite that the drug and the CYP2D6 inhibitor are not the same compound. It is respectfully submitted that the amendment is supported by the specification as originally filed and by the specification of parent application Ser. No. 09/528,978, and that therefore no new matter has been introduced.

The Commissioner is hereby authorized to charge any fees required under 37 C.F.R. §§1.16 and 1.17 or to credit any overpayment to Deposit Account No. 16-1445.

Date: October 16, 2003



Andrea Dorigo
Attorney for Applicant(s)
Reg. No. 47,532

Pfizer Inc
Patent Department
150 East 42nd Street – 5th Floor
New York, NY 10017-5755
(212) 733-1898